Liver abscess (disease)

Summary

Liver abscess (disease) (MONDO:0700051) is a disease and 10 clinical trials. Top therapeutic interventions include cefixime, ceftriaxone, and ciprofloxacin. A subtype of liver disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	liver abscess (disease)
Mondo ID	MONDO:0700051
ICD-10-CM	K75.0
ICD-11	1323593849
NCIT	C99089
SNOMED CT	27916005
Anatomy (UBERON)	UBERON:0002107
Is cancer (heuristic)	no

Also known as: abscess of liver · hepatic abscess

Disease family

This is a subtype of liver disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › liver disorder › liver abscess (disease)

Related subtypes (31): polycystic echinococcosis, autosomal dominant polycystic liver disease, hepatorenal syndrome, hepatitis, hepatic vascular disorder, hepatic porphyria, hepatopulmonary syndrome, fatty liver disease, cirrhosis of liver, drug-induced liver injury, perinatal jaundice due to hepatocellular damage, Aagenaes syndrome, transient familial neonatal hyperbilirubinemia, hyperbiliverdinemia, transient infantile hypertriglyceridemia and hepatosteatosis, idiopathic copper-associated cirrhosis, familial intrahepatic cholestasis, bile duct cyst, nodular regenerative hyperplasia of the liver, hepatoportal sclerosis, primitive portal vein thrombosis, glycogen storage disease due to liver phosphorylase kinase deficiency, liver and intrahepatic bile duct neoplasm, alcoholic liver disease, early-onset familial noncirrhotic portal hypertension, liver failure, fibrotic liver disease, intestinal failure–associated liver disease, membranous obstruction of inferior vena cava, liver disease, severe congenital, cystic fibrosis-related liver disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE3	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00895089	PHASE4	COMPLETED	Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess
NCT06847126	PHASE3	RECRUITING	Empirical Intravenous Beta-Lactam Plus Metronidazole Vs Oral Cefixime Plus Metronidazole for the Treatment of Liver Abscess
NCT03969758	PHASE3	UNKNOWN	Ciprofloxacin Plus Metronidazole Vs Cefixime Plus Metronidazole Therapy for the Treatment of Liver Abscess
NCT06483594	Not specified	NOT_YET_RECRUITING	Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (CHANCE 2407)
NCT06506318	Not specified	RECRUITING	A Joint Model Based on Deep Learning to Predict Multidrug-resistant Klebsiella Pneumoniae Liver Abscess
NCT06519162	Not specified	RECRUITING	Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
NCT06852235	Not specified	NOT_YET_RECRUITING	Characteristics and Treatment Outcome of Liver Abscesses: An Observational Study
NCT01043523	Not specified	COMPLETED	Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.
NCT05213949	Not specified	UNKNOWN	An Observational Study of Risk Factors and Long-term Prognosis of Patients With Liver Abscess in the Real-world
NCT05521139	Not specified	COMPLETED	Risk Factors for Pyogenic Liver Abscess With Carbapenem-resistant Klebsiella Pneumoniae: A Matched Case-control Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CEFIXIME	4	1
CEFTRIAXONE	4	1
CIPROFLOXACIN	4	1
MOXIFLOXACIN	4	1